Enkephalinergic striatal projection neurons become less affected by quinolinic acid than substance P-containing striatal projection neurons as rats age

Experimental Neurology

Volumn 184, Issue 2, 2003, Pages 1034-1042

  Sun, Z ^a   Chen, Q ^a   Reiner, A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Basal ganglia; Enkephalin; Huntington's disease; Quinolinic acid; Substance P

Indexed keywords

ENKEPHALIN; EXCITOTOXIN; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; OLIGONUCLEOTIDE; PREPROENKEPHALIN; PREPROTACHYKININ; QUINOLINIC ACID; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN REGION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DATA ANALYSIS; HISTOCHEMISTRY; HUNTINGTON CHOREA; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MALE; NERVE CELL; NERVE PROJECTION; NONHUMAN; OLIGONUCLEOTIDE PROBE; PATHOGENESIS; PRIORITY JOURNAL; RAT;

EID: 0842299488     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.08.016     Document Type: Article

References (58)

1. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D., Tourtellotte W.W., Reiner A. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 322:1990;1293-1298.
2. Albin R.L., Reiner A., Anderson K.D., Penney J.B., Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implication for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 27:1990;357-365.
3. Albin R.L., Qin Y., Young A.B., Penney J.B., Chesselet M.F. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: an in situ hybridization study. Ann. Neurol. 30:1991;542-549.
4. Auer R.N. Excitotoxic mechanisms, and age-related susceptibility to brain damage in ischemia, hypoglycemia and toxic mussel poisoning. Neurotoxicology. 12:1991;541-546.
5. Bahr B.A., Godshall A.C., Hall R.A., Lynch G. Mouse telencephalon exhibits an age-related decrease in glutamate (AMPA) receptors but no change in nerve terminal markers. Brain Res. 589:1992;320-326.
6. Bannon M.J., Poosch M.S., Haverstick D.M. Preprotachykinin gene expression in the human basal ganglia: characterization of mRNAs and pre-mRNAs produced by alternate RNA splicing. Mol. Brain Res. 12:1992;225-231.
7. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
8. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11:1991;1649-1659.
9. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., Roy D.S., Rosen B.R., Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60:1993;356-359.
10. Burnashev N. Recombinant ionotropic glutamate receptors: functional distinctions imparted by different subunits. Cell. Physiol. Biochem. 3:1993;318-331.
11. Calabresi P., Centonze D., Bernardi G. Cellular factors controling neuronal vulnerability in the brain. A lesson from the striatum. Neurology. 55:2000;1249-1255.
12. Cepeda C., Li Z., Levine M.S. Aging reduces neostriatal responsiveness to N-methyl-D-aspartate and dopamine: an in vitro electrophysiological study. Neuroscience. 73:1996;733-750.
13. Cha J.H., Frey A.S., Alsdrof S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney J.B. Jr., Davies S.W., Bates G.P., Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of huntington's disease. Phil. Trans. R. Soc. London [Bio]. 354:1999;981-989.
14. Chen Q., Harris C., Brown C.S., Howe A., Surmeier D.J., Reiner A. Glutamate-mediated excitotoxic death of cultured striatal neurons is mediated by non-NMDA glutamate receptors. Exp. Neurol. 136:1995;212-224.
15. Chen N., Luo T., Wellington C., Metzler M., McCuthcheon K., Hayden M.R., Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 72:1999;1890-1898.
16. Chesselet M.F., Weiss L., Wuenschell C., Tobin A.J., Affolter H.U. Comparative distribution of mRNAs for glutamic acid decarboxylase, tyrosine hydroxylase, and tachykinins in the basal ganglia: an in situ hybridization study in the rodent brain. J. Comp. Neurol. 262:1987;125-140.
17. Comb M., Seeburg P.H., Adelman J. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature. 295:1982;663-666.
18. Coyle J.T., Schwarcz R. Model for Huntington's chorea: lesion of striatal neurons with kainic acid. Nature. 263:1976;244-246.
19. Ferriero D.M., Simon R.P. Neonatal striatal NADPH-diaphorase neurons are vulnerable to quisqualate and its analogue a-amino-3-methyl-4-isoxazole proprionate (AMPA). Neurosci. Lett. 126:1991;52-56.
20. Figueredo-Cardenas G., Anderson K.D., Chen Q., Veenman C.L., Reiner A. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Exp. Neurol. 129:1994;37-56.
21. Figueredo-Cardenas G., Chen Q., Reiner A. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injections of quinolinic acid in rats. Exp. Neurol. 146:1997;444-457.
22. Figueredo-Cardenas G., Harris C.L., Anderson K.D., Reiner A. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp. Neurol. 149:1998;356-372.
23. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of aging. Nature. 408:2000;239-247.
24. Finn S.F., Hyman B.T., Storey E., Miller J.M., Beal M.F. Effects of aging on quinolinic acid lesions in rat striatum. Brain Res. 562:1991;276-280.
25. Flaherty A.W., Graybiel A.M. Output architecture of the primate putamen. J. Neurosci. 13:1993;3222-3237.
26. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., Coffman J.A., Surmeier D.J., Honig M.G., Carlock L.R., Reiner A. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 19:1999;1189-1202.
27. Glass M., Dragunow M., Faull R.L.M. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAa receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 97:2000;505-519.
28. Gerfen C.R., Young W.S. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460:1988;161-167.
29. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
30. Kawaguchi Y., Wilson C.J., Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10:1990;3421-3438.
31. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86:2001;2667-2677.
32. 2+- permeable AMPA receptors in rat brain by intracellular polyamines generates double rectification. J. Physiol. 486.2:1995;305-312.
33. LoPachin R.M. Jr., Aschner M. Glial-neuronal interactions: relevance to neurotoxic mechanisms. Toxicol. Appl. Pharmacol. 118:1993;141-158.
34. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H.J., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9:2000;1259-1271.
35. Magnusson K.R., Cotman C.W. Effects of aging on NMDA and MK801 binding sites in mice. Brain Res. 604:1993;334-337.
36. Martin J.B. Huntington's disease. New approach to an old problem. Neurology. 34:1984;1059-1072.
37. McDonald J.W., Silverstein F.S., Johnston M.V. Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system. Brain Res. 459:1988;200-203.
38. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., Chesselet M.-F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp. Neurol. 162:2000;328-342.
39. Parent A., Charara A., Pinault D. Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates. Brain Res. 698:1995;280-284.
40. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. fourth ed. 1998;Academic Press, New York.
41. Pelligrini-Giampietro D.E., Bennett M.V.L., Zukin R.S. Differential expression of three glutamate receptor genes in developing rat brain: an in situ hybridization study. Proc. Natl. Acad. Sci. U. S. A. 88:1991;4157-4161.
42. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative disease of the striatum. J. Neurosci. 22:2002;1967-1975.
43. Qin Y., Soghomonian J.-J., Chesselet M.-F. Effects of quinolinic acid on messenger mRNAs encoding somatostatin and glutamic acid decarboxylases in the striatum of adult rats. Exp. Neurol. 115:1992;200-211.
44. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5733-5737.
45. Richfield E.K., Maguire-Zeiss K.A., Cox C., Gilmore J., Voorn P. Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann. Neurol. 37:1995;335-343.
46. Richfield E.K., Maguere-Zeiss D.A., Vonkeman H.E., Voorn P. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 38:1995;852-861.
47. Roberts R.C., Ahn A., Swartz K.J., Beal M.F., DiFiglia M. Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp. Neurol. 124:1993;274-282.
48. Satre J., Pallardó F.V., Vina J. Glutathione, oxidative stress and aging. Age. 19:1996;129-139.
49. Schwarcz R., Foster A.C., French E.D., Whetsell W.O. Jr., Kohler C. Excitoxic models for neurodegenerative disorders. Life Sci. 35:1984;19-32.
50. Taveres R.G., Tasca C.I., Santos C.E.S., Wajner M., Souza D.O., Dutra-Filho C.S. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Life Sci. 11:1999;249-253.
51. Tingley W.G., Roche K.W., Thompson A.K., Huganir R.L. Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature. 364:1993;70-73.
52. Villares J.C., Stavale J.N. Age-related changes in the N-methyl-D-aspartate receptor binding sites within the human basal ganglia. Exp. Neurol. 171:2001;391-404.
53. Wang Y.T., Salter M.W. Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature. 369:1994;233-235.
54. Williams K., Zappia A.M., Pritchett D.B., Shen Y.M., Molinoff P.B. Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol. Pharmacol. 45:1994;803-809.
55. Wu Y., Richard S., Parent A. The organization of the striatal output system: a single-cell juxtacellular labeling study in the rat. Neurosci. Res. 38:2000;49-62.
56. Zeron M.M., Chen N., Moshanver A., Lee A.T.C., Wellington C.L., Hayden M.R., Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 17:2001;41053.
57. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 33:2002;849-860.
58. 2 dopamine receptor-containing neurons to kainic acid. Brain Res. 763:1997;264-266.